利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.057 秒)

    Platelet Aggregation Assays
    4.
    发明申请
    Platelet Aggregation Assays 有权
    血小板聚集测定

    公开(公告)号：US20090220998A1

    公开(公告)日：2009-09-03

    申请号：US12093658

    申请日：2006-11-17

    申请人： Yen-Ming Hsu ,  Lihe Su

    发明人： Yen-Ming Hsu ,  Lihe Su

    IPC分类号： G01N33/567

    CPC分类号： G01N33/6863 ,  G01N33/86

    摘要： The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto.

    摘要翻译： 本发明提供了确定血小板聚集的方法，在给予CD40L结合部分时确定凝血敏感性的方法，以及与其相关的试剂盒。

    Methods of designing and producing novel compounds having improved binding affinity for CD154 or other trimeric proteins
    8.
    发明申请
    Methods of designing and producing novel compounds having improved binding affinity for CD154 or other trimeric proteins 审中-公开
    设计和生产具有改善的对CD154或其他三聚蛋白的结合亲和力的新化合物的方法

    公开(公告)号：US20060172346A1

    公开(公告)日：2006-08-03

    申请号：US11317536

    申请日：2005-12-23

    申请人： Zhongli Zheng ,  Frederick Taylor ,  Christopher Benjamin ,  Yen-Ming Hsu

    发明人： Zhongli Zheng ,  Frederick Taylor ,  Christopher Benjamin ,  Yen-Ming Hsu

    IPC分类号： G01N33/567 ,  C07K16/28

    CPC分类号： C07K16/2875 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70575 ,  C07K2319/00 ,  G01N33/56972 ,  G01N2333/70575 ,  G01N2333/70578 ,  G01N2500/10 ,  G01N2500/20

    摘要： The present invention relates to methods for designing and producing novel CD40:CD154 binding interrupter compounds and methods using these compounds to treat conditions associated with inappropriate CD154 activation in a subject. This invention also relates to novel methods for screening candidate compounds for the properties of specifically binding CD154 and interrupting CD40:CD154 interaction. This invention further relates to methods of improving the binding affinity, or the ability to block CD40/CD154 interaction, of a synthetic molecule for a trimeric protein, such as CD154. These methods comprise converting a first synthetic molecule that cannot promote lattice or aggregate formation of its target trimeric protein to a second synthetic molecule that can promote lattice or aggregate formation of its target trimeric protein. This invention also relates to a two-dimensional lattice or aggregate comprising a plurality of trimeric CD154 on a cell surface or in solution, wherein the lattice or aggregate is formed by bivalent anti-CD154 antibodies associated with trimeric CD154 molecules.

    摘要翻译： 本发明涉及用于设计和生产新型CD40：CD154结合中断剂化合物的方法和使用这些化合物治疗与受试者中不适当的CD154活化相关的病症的方法。 本发明还涉及用于筛选特异性结合CD154和中断CD40：CD154相互作用的性质的候选化合物的新方法。 本发明还涉及提高合成分子对三聚蛋白如CD154的结合亲和力或阻断CD40 / CD154相互作用的能力的方法。 这些方法包括将不能促进其目标三聚体蛋白的晶格或聚集体形成的第一合成分子转化成可以促进其目标三聚体蛋白质的晶格或聚集体形成的第二合成分子。 本发明还涉及在细胞表面或溶液中包含多个三聚体CD154的二维晶格或聚集体，其中所述晶格或聚集体由与三聚体CD154分子相关的二价抗CD154抗体形成。